Nicotinamide levels in glaucoma and their link to eye damage
Treatments studied
Part of Eyes & vision clinical trials.
This study looks at whether a vitamin B3-related substance, called nicotinamide, is lower in the eyes and blood of people with glaucoma. It may help doctors understand why glaucoma damages the optic nerve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of open-angle glaucoma (a common type of glaucoma).
- For some groups, you need to have high eye pressure (over 21 mmHg) despite taking maximum eye drops and be planning glaucoma surgery.
- For other groups, your eye pressure must be controlled (21 mmHg or lower) with eye drops.
- You cannot have had any previous eye surgery (other than cataract surgery).
- You cannot have other eye diseases besides glaucoma or cataracts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a vitamin B3 supplement called nicotinamide can help slow down vision loss in people with glaucoma. It is for those with moderate disease who are already on treatment.
This trial studies whether nicotinamide (a form of vitamin B3/niacin) can slow or affect glaucoma progression. You may be eligible if you have newly diagnosed, untreated glaucoma or if you have treated glaucoma with measurable visual field changes.
This trial tests whether NAD precursor supplements can improve nerve health and vision in people with glaucoma. If you have glaucoma with mild to moderate vision loss, this study may help understand if these supplements could protect your optic nerve.
This study looks at whether certain glaucoma eye drops might help protect the nerve cells in your eye over time. If you've been using the same type of eye drop for a few years, researchers will review your past eye tests to see how your vision and eye health have changed.
This study tests whether metformin can slow damage to the optic nerve in people with glaucoma. It uses eye scans and vision tests to look for changes over time, aiming to help preserve sight.
This Phase 1 study tests an insulin-based eye treatment to see if it’s safe and potentially helpful for people with glaucoma-related optic nerve damage. If you may be eligible, you’ll have a close eye exam and repeated vision testing, mainly focused on one study eye.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.